SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, today announced the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.